• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

并存地中海贫血、免疫性血小板减少性紫癜和伴有骨质减少的多发性骨髓瘤:一名成年亚洲男性患者的复杂血液病例

Coexisting Thalassemia, Immune Thrombocytopenic Purpura, and Multiple Myeloma With Osteopenia: Complex Hematologic Case in an Adult Asian Male Patient.

作者信息

Chambi-Torres Javier B, Angly Sohair, Michel George

机构信息

Internal Medicine, Larkin Community Hospital, South Miami, USA.

出版信息

Cureus. 2024 Dec 8;16(12):e75338. doi: 10.7759/cureus.75338. eCollection 2024 Dec.

DOI:10.7759/cureus.75338
PMID:39776720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11706632/
Abstract

We report a rare case of a 45-year-old Asian male patient with concurrent multiple myeloma (MM), immune thrombocytopenic purpura (ITP), and thalassemia trait, presenting with severe thrombocytopenia, back pain, and bleeding manifestations. The diagnosis was established through a combination of laboratory findings, imaging, and bone marrow biopsy, revealing 90% plasma cell involvement and KRAS/BRCA2 mutations. Management focused on controlling ITP with corticosteroids, rituximab, and platelet transfusions while addressing immunosuppression risks. Due to logistical limitations, MM-specific therapy was deferred, and the patient was stabilized for transfer to continue treatment in his home country. This case highlights the challenges of managing overlapping hematologic disorders and underscores the importance of individualized care in complex presentations.

摘要

我们报告了一例罕见病例,一名45岁的亚洲男性患者同时患有多发性骨髓瘤(MM)、免疫性血小板减少性紫癜(ITP)和地中海贫血特质,表现为严重血小板减少、背痛和出血表现。通过实验室检查结果、影像学检查和骨髓活检相结合确诊,显示90%的浆细胞受累以及KRAS/BRCA2突变。治疗重点是使用皮质类固醇、利妥昔单抗和血小板输注来控制ITP,同时应对免疫抑制风险。由于后勤限制,MM特异性治疗被推迟,患者病情稳定后转至其祖国继续治疗。该病例凸显了管理重叠血液系统疾病的挑战,并强调了在复杂病例中个体化治疗的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1852/11706632/e889df28232c/cureus-0016-00000075338-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1852/11706632/9bc5c5a00ff1/cureus-0016-00000075338-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1852/11706632/5b956f42bc5c/cureus-0016-00000075338-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1852/11706632/e889df28232c/cureus-0016-00000075338-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1852/11706632/9bc5c5a00ff1/cureus-0016-00000075338-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1852/11706632/5b956f42bc5c/cureus-0016-00000075338-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1852/11706632/e889df28232c/cureus-0016-00000075338-i03.jpg

相似文献

1
Coexisting Thalassemia, Immune Thrombocytopenic Purpura, and Multiple Myeloma With Osteopenia: Complex Hematologic Case in an Adult Asian Male Patient.并存地中海贫血、免疫性血小板减少性紫癜和伴有骨质减少的多发性骨髓瘤:一名成年亚洲男性患者的复杂血液病例
Cureus. 2024 Dec 8;16(12):e75338. doi: 10.7759/cureus.75338. eCollection 2024 Dec.
2
Severe Immune Thrombocytopenic Purpura in a Pediatric Patient With Fanconi Anemia: A Case Report.一名患有范可尼贫血的儿科患者的严重免疫性血小板减少性紫癜:病例报告
Cureus. 2024 Sep 9;16(9):e68973. doi: 10.7759/cureus.68973. eCollection 2024 Sep.
3
Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature.一名已知患有特发性(免疫性)血小板减少性紫癜的患者发生产后血栓性血小板减少性紫癜:病例报告及文献综述
J Med Case Rep. 2018 Jun 1;12(1):147. doi: 10.1186/s13256-018-1692-1.
4
Concurrence of immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura: a case report and review of the literature.免疫性血小板减少性紫癜与血栓性血小板减少性紫癜并存:病例报告及文献复习。
J Med Case Rep. 2023 Feb 8;17(1):38. doi: 10.1186/s13256-023-03762-y.
5
Immune thrombocytopenic purpura presenting in a patient after renal transplant for diabetic nephropathy.一名因糖尿病肾病接受肾移植的患者出现免疫性血小板减少性紫癜。
BMC Nephrol. 2018 Mar 20;19(1):69. doi: 10.1186/s12882-018-0868-7.
6
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.接受免疫检查点抑制剂治疗的黑色素瘤患者的血小板减少症。
J Immunother Cancer. 2017 Feb 21;5:8. doi: 10.1186/s40425-017-0210-0. eCollection 2017.
7
Thrombotic thrombocytopenic purpura or immune thrombocytopenia in a sickle cell/β+-thalassemia patient: a rare and challenging condition.镰状细胞/β+地中海贫血患者出现血栓性血小板减少性紫癜或免疫性血小板减少症:一种罕见且具有挑战性的病症。
Transfus Apher Sci. 2014 Oct;51(2):175-7. doi: 10.1016/j.transci.2014.09.001. Epub 2014 Sep 16.
8
[Idiopathic thrombocytopenic purpura in children].[儿童特发性血小板减少性紫癜]
Med Pregl. 1998 Mar-Apr;51(3-4):127-34.
9
Suspected Immune Thrombocytopenic Purpura Induced by Lenalidomide for the Treatment of Myelodysplastic Syndrome with Deletion of Chromosome 5q: A Case Report.来那度胺治疗伴有5号染色体长臂缺失的骨髓增生异常综合征引发疑似免疫性血小板减少性紫癜:一例报告
Tohoku J Exp Med. 2023 Jan 21;259(2):113-119. doi: 10.1620/tjem.2022.J104. Epub 2022 Dec 1.
10
Successful treatment of refractory secondary immune thrombocytopenia (antiphospholipid antibody syndrome-associated) with the combination of rituximab and romiplostim at the cost of severe bone pain: A case report and review of literature.成功治疗难治性继发性免疫性血小板减少症(抗磷脂抗体综合征相关):利妥昔单抗联合罗米司亭治疗,伴有严重骨痛:病例报告及文献复习。
J Oncol Pharm Pract. 2021 Jan;27(1):253-257. doi: 10.1177/1078155220935490. Epub 2020 Jul 1.

本文引用的文献

1
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.多发性骨髓瘤的风险和结局与 DNA 修复基因中的致病性种系变异有关。
Blood Cancer Discov. 2024 Nov 1;5(6):428-441. doi: 10.1158/2643-3230.BCD-23-0208.
2
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.多发性骨髓瘤,第 2.2024 版,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2023 Dec;21(12):1281-1301. doi: 10.6004/jnccn.2023.0061.
3
Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma.
NRAS、KRAS和BRAF突变激活MAPK对新诊断多发性骨髓瘤临床结局的影响
Hematol Oncol. 2023 Dec;41(5):912-921. doi: 10.1002/hon.3208. Epub 2023 Jul 15.
4
Latest Development in Multiple Myeloma.多发性骨髓瘤的最新进展
Cancers (Basel). 2020 Sep 7;12(9):2544. doi: 10.3390/cancers12092544.
5
Hematological Diseases and Osteoporosis.血液系统疾病与骨质疏松症
Int J Mol Sci. 2020 May 16;21(10):3538. doi: 10.3390/ijms21103538.
6
Multiple myeloma with concurrent immune thrombocytopenic purpura.多发性骨髓瘤合并免疫性血小板减少性紫癜。
Ecancermedicalscience. 2020 Feb 20;14:1012. doi: 10.3332/ecancer.2020.1012. eCollection 2020.
7
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines.KRAS基因外显子4突变影响人多发性骨髓瘤细胞系中的MEK/ERK和PI3K/AKT信号通路。
Cancers (Basel). 2020 Feb 16;12(2):455. doi: 10.3390/cancers12020455.
8
Hematologic malignancies in thalassemia: Adding new cases to the repertoire.地中海贫血中的血液系统恶性肿瘤:增加新病例到病例库中。
Am J Hematol. 2017 May;92(5):E68-E70. doi: 10.1002/ajh.24681. Epub 2017 Feb 27.
9
[Multiple myeloma developing in a patient with immune thrombocytopenia].[免疫性血小板减少症患者发生多发性骨髓瘤]
Rinsho Ketsueki. 2016 May;57(5):630-3. doi: 10.11406/rinketsu.57.630.
10
PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.PJ34,一种多聚(ADP-核糖)聚合酶(PARP)抑制剂,通过靶向 FA/BRCA 通路,逆转了多柔比星耐药多发性骨髓瘤细胞系 RPMI8226/R 对美法仑的耐药性,并抑制了 DNA 双链断裂的修复。
Int J Oncol. 2015 Jan;46(1):223-32. doi: 10.3892/ijo.2014.2726. Epub 2014 Oct 23.